Literature DB >> 29992512

Hepatitis C virus genotype 4-infection and interferon-free treatment in Egypt.

Tatsuo Kanda1, Shunichi Matsuoka2, Mitsuhiko Moriyama2.   

Abstract

Entities:  

Keywords:  DAA; Genotype 4; HCV; SVR; Thyroid-stimulating hormone

Mesh：

Substances：

Year:  2018        PMID： 29992512     DOI： 10.1007/s12072-018-9883-9

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  11 in total

1.  High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy.

Authors:  Rasha Eletreby; Mohamed Said; Zeinab Abdellatif; Yasmin Saad; Magdy ElSerafy; Hosam Dabes; Kadry ElSaeed; Yehia El-Shazly; Wahid Doss
Journal:  Hepatol Int       Date:  2018-02-14       Impact factor: 6.047

2.  Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.

Authors:  G Shiha; R Soliman; M ElBasiony; A A Hassan; N N H Mikhail
Journal:  Hepatol Int       Date:  2018-04-16       Impact factor: 6.047

3.  Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Authors:  Adel Abdel-Moneim; Alaa Aboud; Mohamed Abdel-Gabaar; Mohamed I Zanaty; Mohamed Ramadan
Journal:  Hepatol Int       Date:  2018-05-12       Impact factor: 6.047

4.  Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt.

Authors:  H Omar; W El Akel; T Elbaz; M El Kassas; K Elsaeed; H El Shazly; M Said; M Yousif; A A Gomaa; A Nasr; M AbdAllah; M Korany; S A Ismail; M K Shaker; W Doss; G Esmat; I Waked; Y El Shazly
Journal:  Aliment Pharmacol Ther       Date:  2017-11-29       Impact factor: 8.171

5.  Thyroid disorders in chronic hepatitis C.

Authors:  Alessandro Antonelli; Clodoveo Ferri; Alessandro Pampana; Poupak Fallahi; Claudia Nesti; Martina Pasquini; Santino Marchi; Ele Ferrannini
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

Review 6.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

Review 7.  APASL consensus statements and recommendation on treatment of hepatitis C.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-04-29       Impact factor: 6.047

8.  Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.

Authors:  Gamal Shiha; Gamal Esmat; Mohamed Hassany; Reham Soliman; Mohamed Elbasiony; Rabab Fouad; Aisha Elsharkawy; Radi Hammad; Wael Abdel-Razek; Talaat Zakareya; Kathryn Kersey; Benedetta Massetto; Anu Osinusi; Sophia Lu; Diana M Brainard; John G McHutchison; Imam Waked; Wahid Doss
Journal:  Gut       Date:  2018-04-17       Impact factor: 23.059

9.  Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA.

Authors:  T Kanda; O Yokosuka; F Imazeki; M Tanaka; Y Shino; H Shimada; T Tomonaga; F Nomura; K Nagao; T Ochiai; H Saisho
Journal:  J Viral Hepat       Date:  2004-11       Impact factor: 3.728

10.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962
View more
  3 in total

1.  Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment.

Authors:  Fatma Amer; Monkez M Yousif; Noha M Hammad; Damir Garcia-Cehic; Josep Gregori; Ariadna Rando-Segura; Leonardo Nieto-Aponte; Juan Ignacio Esteban; Francisco Rodriguez-Frias; Josep Quer
Journal:  Infect Drug Resist       Date:  2019-09-10       Impact factor: 4.003

2.  Chemokine receptor CXCR6 gene polymorphism and treatment response of chronic hepatitis C virus in Egyptian patients.

Authors:  Mona M Hassona; Tamer Fouad; Merhan Osama Helmi; Heba Samy Mohammed Ghanem; Heba E Abd Elrhman; Eman Abdelsameea
Journal:  Clin Exp Hepatol       Date:  2021-12-23

3.  Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease.

Authors:  Mahmoud Saif-Al-Islam; Usama M Abdelaal; Mustafa Adel Younis; Hisham A Alghany Algahlan; Safaa Khalaf
Journal:  Gastroenterol Res Pract       Date:  2021-05-23       Impact factor: 2.260
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.